Biocartis strengthens management team with general counsel

18-Jan-2013 - Biocartis announced that Inge Basteleurs has joined the company as General Counsel. Inge will be a member of Biocartis’ Executive Committee and a director of Biocartis NV. Inge Basteleurs brings to Biocartis a 17-year career as a senior international executive within the biotechnology and ...

Multiplicom receives €200,000 grant for novel non-invasive pre-natal test

IWT grant to support development of early aneuploidy detection during pregnancy

13-Jun-2012 - Multiplicom, a molecular diagnostics company specializing in the design, development, production and commercialization of molecular genetic tests based on massively parallel sequencing, announced that it has been awarded a €200,000 grant from the Flemish agency for Innovation by Science and ...

Karyopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors

13-Oct-2011 - Karyopharm Therapeutics Inc. has initiated an exclusive collaboration in the area of Selective Inhibitors of Nuclear Export (SINE) modulators of the CRM1 protein with the Rega Institute for Medical Research, a part of the Katholieke University of Leuven (K.U.Leuven), Belgium. The nuclear ...

FORMAC obtains EMA Orphan Drug Designation for FP110

22-Mar-2011 - FORMAC Pharmaceuticals N.V. announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to FORMAC's FP110.This Orphan Drug Designation follows a similar decision from the Food & Drug Administration (FDA). It is another important milestone for the program, following the ...

European Investment Fund and K.U.Leuven invest 16 million euro in Centre for Drug Design and Discovery

22-Sep-2010 - The Katholieke Universiteit Leuven and the European Investment Fund (EIF) are investing an additional 16 million euro in the Centre for Drug Design and Discovery (CD3), thereby increasing the total capital of CD3 to 24 million euro. CD3 allows fundamental innovative biomedical research carried ...

Katholieke Universiteit Leuven enters into license agreement with Pfizer for the development of new anti-HIV drugs

16-Sep-2010 - Katholieke Universiteit Leuven (K.U.Leuven, Belgium) announced that on July 29th, 2010 they entered into a license agreement with Pfizer. The license agreement grants Pfizer exclusive and sublicenseable worldwide rights to further develop and commercialise K.U.Leuven’s compounds with a new ...

Roche and reMYND enter into a strategic alliance to develop treatments for Parkinson’s and Alzheimer’s disease

10-Sep-2010 - Roche and reMYND announced that they have entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients by inhibiting alpha-synuclein and tau toxicity. The collaboration will focus on two of reMYND’s pre-clinical small ...

PharmaNeuroBoost’s lead product in major depression receives IND approval from FDA

30-Jun-2010 - PharmaNeuroBoost NV (PNB) reported that the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application for PNB01. PNB01 is a proprietary owned, fixed dose combination of citalopram and low dose pipamperone, and is under development for the treatment of Major ...

Promising Proof-of-Concept study results to be reported for PNB01 in Major Depression

09-Feb-2010 - Pharmaneuroboost (PNB) reported that the results of it’s phase II Proof-of-Concept study with PNB01 in Major Depression will be presented at the 18th European Congress of Psychiatry on March 2nd in Munich. “The results are impressive and promising”, says Chief Investigator Alan Wade (Glasgow), ...